Scholars Central

Conference abstractPublished 23 Jul 2018

Preliminary results of nimotuzumab plus concurrent IMRT and chemotherapy on cervical cancer

Authors: Qu Ang

Peking University Third Hospital, China

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Objective: To evaluate the safety and effi cacy of nimotuzumab plus concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy of unresectable cervical cancer. Methods: From December 2013 to February 2017, 34 patients with cervical cancer on stage (FIGO) IB2-IVB were received concurrent chemoradiotherapy plus nimotuzumab. Th e prescription dose of radiation was 50.4 Gy/28f on pelvic fi eld with or with not extended fi eld radiation. An additional 30-36 Gy to Point A were delivered with high-dose-rate techniques. Cisplatin of 40 mg/m2 and nimotuzumab of 200mg were infused intravenously once weekly during RT for 6 weeks. Th e main outcome measure was toxicity evaluated by CTCAE 4.0. Secondary outcome measure was short-term outcome evaluated by RESIST1.1. Result: Th e median of followed up time was 23.4 months (8.3-45.5 months). Almost all patients were local advantaged cancer except 2 patients with distant metastases. All patients received external radiotherapy. 2 patients were not treated with brachytherapy. 6 patients failed to fi nish radiotherapy within 56 days. All of 34 patients received concurrent treatment with nimotuzumab for 6 times. 2 patients refused chemotherapy. Th ere was no life-threatening toxicity. Grade 1/2 of nausea vomiting and diarrhea were 70.6% (24/34), 32.4% (11/34) and 52.9% (18/34), respectively. Grade 3 of leucopenia, granulopenia thrombocytopenia and anemia were 52.9% (18/34), 17.6% (6/34), 14.7% (5/34), and 11.8% (4/34) respectively. Grade 3 of nausea and vomiting were 8.8% (3/34) and 2.9% (1/34), respectively. No grade 3 of anorectal infl ammation. Rectovaginal fi stula was observed in one case 6 months aft er radiotherapy, and operation was performed. Surgical treatment of intestinal obstruction was performed in one case. 2 cases got vaginal stenosis. Th e objective response rate was 100%. Complete response was achieved in 29 cases (85.3%) and partial response in 5 cases (14.7%). Conclusion: Nimotuzumab plus concurrent IMRT and chemotherapy may represent an eff ective and well-tolerated treatment in patients with unresectable cervical cancer.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Qu Ang”